MacOrtho is thrilled to announce that the PARITY trial has just enrolled its 100th and 101st participants worldwide! Currently, 30 sites are actively screening and enrolling participants into the PARITY trial across Canada, the United States, Australia and Argentina.
The PARITY trial is investigating whether long duration post-operative antibiotics decreases the rate of surgical site infections compared to a standard short duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-center randomized trials were possible in their specialty. The success of PARITY has demonstrated that these types of studies are, in fact, possible.